Life sciences innovation in advanced economies is under threat—not from a lack of talent, ideas, or scientific leadership, but from policy failures. The EU, Canada, Japan, and other major markets are ...
East Hanover, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease, the second ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
April 26, 2023 Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities ...
Animal research is key to many of the great medical advances of today, including cancer treatments; medicines to treat neurological diseases such as multiple sclerosis, medicines for diseases that ...
Subscribe to get the latest news and updates from Novartis directly to your inbox. Unsubscribe if you no longer want to receive them. Select 'Publication Order Form' if you would like Novartis reports ...
Consumer Medicine Information, or CMI, provides clear, easy-to-understand information to consumers and their carers about how to use their medicines. CMI leaflets for Novartis Pharmaceuticals products ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Production and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy ...
Пациентам и врачам «Новартис» сотрудничает с пациентским сообществом по всему миру, чтобы найти новые способы улучшить и продлить жизни людей. Наши значительные инвестиции в исследования и разработки ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results